Robin Crawford
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robin Crawford has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Alan F. Horgan
Freeman Hospital
1 shared publication - Andrew B. Gill
Department of Radiology, University of Cambridge, Cambridge, UK
1 shared publication - Anne-Laure Grignon
Dept of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, UK
1 shared publication - Anuja Chatterjee
Merck Sharp & Dohme Limited, Maidenhead, UK
1 shared publication - Cara Brodie
Cancer Research UK Cambridge Institute, University of Cambridge
1 shared publication - Charlotte Hodgkin
Cancer Research UK Cambridge Institute, University of Cambridge , Cambridge, United Kingdom, CB2 0RE
1 shared publication
Latest Publications
- Open Access
- 2 May 2022
- Published by Oxford University Press (OUP) in BJR|Open
- Vol. 4 (1) , 20210078
Magnetization transfer imaging of ovarian cancer: initial experiences of correlation with tissue cellularity and changes following neoadjuvant chemotherapy
Objectives: To investigate the relationship between magnetization transfer (MT) imaging and tissue macromolecules in high-grade serous ovarian cancer (HGSOC) and whether MT ratio (MTR) changes following neoadjuvant chemotherapy (NACT). Methods: This was a prospective observational study. 12 HGSOC patients were imaged before treatment. MTR was compared to quantified tissue histology and immunohistochemistry. For a subset of patients (n = 5), MT imaging was repeated after NACT. The Shapiro–Wilk test was used to assess for normality of data and Spearman’s rank-order or Pearson’s correlation tests were then used to compare MTR with tissue quantifications. The Wilcoxon signed-rank test was used to assess for changes in MTR after treatment. Results: Treatment-naïve tumour MTR was 21.9 ± 3.1% (mean ± S.D.). MTR had a positive correlation with cellularity, rho = 0.56 (p < 0.05) and a negative correlation with tumour volume, ρ = −0.72 (p = 0.01). MTR did not correlate with the extracellular proteins, collagen IV or laminin (p = 0.40 and p = 0.90). For those patients imaged before and after NACT, an increase in MTR was observed in each case with mean MTR 20.6 ± 3.1% (median 21.1) pre-treatment and 25.6 ± 3.4% (median 26.5) post-treatment (p = 0.06). Conclusion: In treatment-naïve HGSOC, MTR is associated with cellularity, possibly reflecting intracellular macromolecular concentration. MT may also detect the HGSOC response to NACT, however larger studies are required to validate this finding. Advances in knowledge: MTR in HGSOC is influenced by cellularity. This may be applied to assess for cell changes following treatment.
- 2 May 2022
- Published by Oxford University Press (OUP) in BJR|Open
- Vol. 4 (1) , 20210078
Open AccessMagnetization transfer imaging of ovarian cancer: initial experiences of correlation with tissue cellularity and changes following neoadjuvant chemotherapy
Objectives: To investigate the relationship between magnetization transfer (MT) imaging and tissue macromolecules in high-grade serous ovarian cancer (HGSOC) and whether MT ratio (MTR) changes following neoadjuvant chemotherapy (NACT). Methods: This was a prospective observational study. 12 HGSOC patients were imaged before treatment. MTR was compared to quantified tissue histology and immunohistochemistry. For a subset of patients (n = 5), MT imaging was repeated after NACT. The Shapiro–Wilk test was used to assess for normality of data and Spearman’s rank-order or Pearson’s correlation tests were then used to compare MTR with tissue quantifications. The Wilcoxon signed-rank test was used to assess for changes in MTR after treatment. Results: Treatment-naïve tumour MTR was 21.9 ± 3.1% (mean ± S.D.). MTR had a positive correlation with cellularity, rho = 0.56 (p < 0.05) and a negative correlation with tumour volume, ρ = −0.72 (p = 0.01). MTR did not correlate with the extracellular proteins, collagen IV or laminin (p = 0.40 and p = 0.90). For those patients imaged before and after NACT, an increase in MTR was observed in each case with mean MTR 20.6 ± 3.1% (median 21.1) pre-treatment and 25.6 ± 3.4% (median 26.5) post-treatment (p = 0.06). Conclusion: In treatment-naïve HGSOC, MTR is associated with cellularity, possibly reflecting intracellular macromolecular concentration. MT may also detect the HGSOC response to NACT, however larger studies are required to validate this finding. Advances in knowledge: MTR in HGSOC is influenced by cellularity. This may be applied to assess for cell changes following treatment.
- Open Access
- 6 April 2020
- Published by Springer Nature in BMC Public Health
- Vol. 20 (1) , 1-8
The costs of treating vaginal and vulval cancer in England (2009–2015)
Background: Human papillomavirus (HPV) infection is a pre-requisite for cervical cancer, which represents the third most common cancer among women worldwide. A causal relationship also exists between HPV and cancer in other areas of the female reproductive system including the vagina and vulva. Whilst the incidence of vaginal cancer in the UK has remained relatively stable over the past 25 years, vulval cancer rates are increasing. A body of literature exists on the epidemiology and aetiology of vaginal and vulval cancer, but little is known about the economic burden. The objective of this study was to quantify the costs of treating these cancers on the National Health Service (NHS) in England. Methods: Inpatient and outpatient episodes were derived from Hospital Episode Statistics (HES). Health Resource Group (HRG) tariffs and National Reference Costs were used to estimate the cost of treating pre-cancerous and invasive vaginal and vulval lesions in England. Results: The study showed that for the 5 years from 2009/2010 to 2014/2015 the total cost associated with pre-cancerous and invasive vaginal and vulval lesions was over £14 million per year on average (95% of which was attributed to inpatient costs). Vulval cancer accounted for the largest proportion; an estimated 60% of the total cost (£8.82 million). On average 4316 patients per year in England were admitted to hospital and 912 patients attended outpatient settings for pre-cancerous and invasive disease of the vagina and vulva. Conclusion: The results indicate that vaginal and vulval cancer cost the English health care system over £14 million per year. Given the causal role of HPV in a proportion of these cancers, preventative measures such as the national HPV immunisation programme have the potential to reduce the economic burden. To ensure optimal use of NHS resources, it is important that future economic evaluations of such preventative measures consider the full burden of HPV related disease.
- 6 April 2020
- Published by Springer Nature in BMC Public Health
- Vol. 20 (1) , 1-8
Open AccessThe costs of treating vaginal and vulval cancer in England (2009–2015)
Background: Human papillomavirus (HPV) infection is a pre-requisite for cervical cancer, which represents the third most common cancer among women worldwide. A causal relationship also exists between HPV and cancer in other areas of the female reproductive system including the vagina and vulva. Whilst the incidence of vaginal cancer in the UK has remained relatively stable over the past 25 years, vulval cancer rates are increasing. A body of literature exists on the epidemiology and aetiology of vaginal and vulval cancer, but little is known about the economic burden. The objective of this study was to quantify the costs of treating these cancers on the National Health Service (NHS) in England. Methods: Inpatient and outpatient episodes were derived from Hospital Episode Statistics (HES). Health Resource Group (HRG) tariffs and National Reference Costs were used to estimate the cost of treating pre-cancerous and invasive vaginal and vulval lesions in England. Results: The study showed that for the 5 years from 2009/2010 to 2014/2015 the total cost associated with pre-cancerous and invasive vaginal and vulval lesions was over £14 million per year on average (95% of which was attributed to inpatient costs). Vulval cancer accounted for the largest proportion; an estimated 60% of the total cost (£8.82 million). On average 4316 patients per year in England were admitted to hospital and 912 patients attended outpatient settings for pre-cancerous and invasive disease of the vagina and vulva. Conclusion: The results indicate that vaginal and vulval cancer cost the English health care system over £14 million per year. Given the causal role of HPV in a proportion of these cancers, preventative measures such as the national HPV immunisation programme have the potential to reduce the economic burden. To ensure optimal use of NHS resources, it is important that future economic evaluations of such preventative measures consider the full burden of HPV related disease.
- 1 January 2013
- Published by Elsevier in Gynecologic Oncology
- Vol. 128 (1) , 148-149
The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer: Is the evidence strong enough?
- 1 January 2013
- Published by Elsevier in Gynecologic Oncology
- Vol. 128 (1) , 148-149
The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer: Is the evidence strong enough?
- Open Access
- 27 June 2012
- Published by Springer Nature in Perioperative Medicine
- Vol. 1 (1) , 2
Perioperative fluid management: Consensus statement from the enhanced recovery partnership
- 27 June 2012
- Published by Springer Nature in Perioperative Medicine
- Vol. 1 (1) , 2
Open AccessPerioperative fluid management: Consensus statement from the enhanced recovery partnership
- Open Access
- 2 November 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 473
High prevalence of HPV in non-cervical sites of women with abnormal cervical cytology
Background: Human papillomaviruses (HPV) are causally associated with ano-genital and a subset of head and neck cancers. Rising incidence of HPV+ anal cancers and head and neck cancers have now been demonstrated in the developed world over the last decade. The majority of published data on HPV prevalence at the anal and oro-pharyngeal sites are from studies of higher-risk populations. There is a paucity of data on the prevalence of HPV at non-cervical sites in lower risk, non-HIV+ women and this study was designed to provide initial pilot data on a population of women recalled for colposcopy as part of the UK cervical screening programme. Methods: 100 non-HIV+ women with abnormal cervical cytology, attending clinic for colposcopic examination were recruited. Swabs from the oro-pharyngeal, anal and cervical sites were taken and DNA extracted. HPV detection and genotyping were performed using a standardised, commercially available PCR-line blot assay, which is used to genotype 37 HPV subtypes known to infect the ano-genital and oro-pharyngeal areas. Strict sampling and laboratory precautions were taken to prevent cross-contamination. Results: There was a very high prevalence of HPV infection at all three sites: 96.0%, 91.4% and 92.4% at the cervix, anus and oro-pharynx, respectively. Multiple HPV subtype infections were dominant at all 3 mucosal sites. At least one or more HR genotype was present at both the cervix/anus in 39/52 (75.0%) patients; both the cervix/oro-pharynx in 48/56 (85.7%) patients; and both the anus/oro-pharynx in 39/52 (75.0%) patients. HPV 16 infection was highly dominant across all mucosal sites, with over a 2-fold increase over the next most prevalent subtype (HPV 31). Conclusions: Women with abnormal smears have widespread infection with high-risk HPV at the cervical, anal and oro-pharyngeal mucosal sites and may represent a higher risk population for HPV disease in the future.
- 2 November 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 473
Open AccessHigh prevalence of HPV in non-cervical sites of women with abnormal cervical cytology
Background: Human papillomaviruses (HPV) are causally associated with ano-genital and a subset of head and neck cancers. Rising incidence of HPV+ anal cancers and head and neck cancers have now been demonstrated in the developed world over the last decade. The majority of published data on HPV prevalence at the anal and oro-pharyngeal sites are from studies of higher-risk populations. There is a paucity of data on the prevalence of HPV at non-cervical sites in lower risk, non-HIV+ women and this study was designed to provide initial pilot data on a population of women recalled for colposcopy as part of the UK cervical screening programme. Methods: 100 non-HIV+ women with abnormal cervical cytology, attending clinic for colposcopic examination were recruited. Swabs from the oro-pharyngeal, anal and cervical sites were taken and DNA extracted. HPV detection and genotyping were performed using a standardised, commercially available PCR-line blot assay, which is used to genotype 37 HPV subtypes known to infect the ano-genital and oro-pharyngeal areas. Strict sampling and laboratory precautions were taken to prevent cross-contamination. Results: There was a very high prevalence of HPV infection at all three sites: 96.0%, 91.4% and 92.4% at the cervix, anus and oro-pharynx, respectively. Multiple HPV subtype infections were dominant at all 3 mucosal sites. At least one or more HR genotype was present at both the cervix/anus in 39/52 (75.0%) patients; both the cervix/oro-pharynx in 48/56 (85.7%) patients; and both the anus/oro-pharynx in 39/52 (75.0%) patients. HPV 16 infection was highly dominant across all mucosal sites, with over a 2-fold increase over the next most prevalent subtype (HPV 31). Conclusions: Women with abnormal smears have widespread infection with high-risk HPV at the cervical, anal and oro-pharyngeal mucosal sites and may represent a higher risk population for HPV disease in the future.
- Open Access
- 12 April 2011
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 119 (2) , 160-165
Improvements in survival of gynaecological cancer in the Anglia region of England: are these an effect of centralisation of care and use of multidisciplinary management?
Please cite this paper as:Crawford R, Greenberg D. Improvements in survival of gynaecological cancer in the Anglia region of England: are these an effect of centralisation of care and use of multidisciplinary management? BJOG 2012;119:160–165.Objective Our hypothesis is that the adoption of Department of Health (DH) guidance has led to an improvement in outcome in gynaecological cancer survival.Setting In 1999 the DH in England introduced theImproving Outcomes in Gynaecological Cancerguidance, advising case management by multidisciplinary teams with surgical concentration in specialist hospitals. This guidance was rapidly adopted in the East of England, with a population of 2.5 million.Population The population of the Anglia Cancer Network was approximately 2.3 million.Methods From 1996 to 2003, details of 3406 cases of gynaecological cancer were identified in the Anglia region of England. Survival analysis was performed by Cox proportional hazards regression, relative to cases diagnosed in 1996.Main outcome measure Primary endpoint was survival.Results The survival rates for cases diagnosed between 1996 and 1999 were broadly the same across the time period, with a marked improvement taking place in 2000, and continuing to 2003 (HR 0.71, 95% CI 0.64–0.79, comparing 2000–03 with 1996–99 diagnoses), for all gynaecological sites combined. Adjustment for treatments or method of case follow‐up did not attenuate these improvements. There was a concurrent change towards major surgery being performed in specialist centres from 2000.Conclusions The adoption of the 1999 guidance on gynaecological cancer, which included multidisciplinary case management and centralisation of surgery, resulted in a marked step‐change improvement in survival of gynaecological cancer in an area of eastern England in 2000.
- 12 April 2011
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 119 (2) , 160-165
Open AccessImprovements in survival of gynaecological cancer in the Anglia region of England: are these an effect of centralisation of care and use of multidisciplinary management?
Please cite this paper as:Crawford R, Greenberg D. Improvements in survival of gynaecological cancer in the Anglia region of England: are these an effect of centralisation of care and use of multidisciplinary management? BJOG 2012;119:160–165.Objective Our hypothesis is that the adoption of Department of Health (DH) guidance has led to an improvement in outcome in gynaecological cancer survival.Setting In 1999 the DH in England introduced theImproving Outcomes in Gynaecological Cancerguidance, advising case management by multidisciplinary teams with surgical concentration in specialist hospitals. This guidance was rapidly adopted in the East of England, with a population of 2.5 million.Population The population of the Anglia Cancer Network was approximately 2.3 million.Methods From 1996 to 2003, details of 3406 cases of gynaecological cancer were identified in the Anglia region of England. Survival analysis was performed by Cox proportional hazards regression, relative to cases diagnosed in 1996.Main outcome measure Primary endpoint was survival.Results The survival rates for cases diagnosed between 1996 and 1999 were broadly the same across the time period, with a marked improvement taking place in 2000, and continuing to 2003 (HR 0.71, 95% CI 0.64–0.79, comparing 2000–03 with 1996–99 diagnoses), for all gynaecological sites combined. Adjustment for treatments or method of case follow‐up did not attenuate these improvements. There was a concurrent change towards major surgery being performed in specialist centres from 2000.Conclusions The adoption of the 1999 guidance on gynaecological cancer, which included multidisciplinary case management and centralisation of surgery, resulted in a marked step‐change improvement in survival of gynaecological cancer in an area of eastern England in 2000.
- Open Access
- 12 January 2011
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 118 (3) , 271-273
The impact of mode of anaesthesia on postoperative recovery from fast-track abdominal hysterectomy: a randomised clinical trial
- 12 January 2011
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 118 (3) , 271-273
Open AccessThe impact of mode of anaesthesia on postoperative recovery from fast-track abdominal hysterectomy: a randomised clinical trial
- Open Access
- 4 November 2010
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 118 (1) , 28-33
Utility of peritoneal lavage cytology during laparoscopic salpingo-oophorectomy: a retrospective analysis
Please cite this paper as: Haldar K, Giamougiannis P, Crawford R. Utility of peritoneal lavage cytology during laparoscopic salpingo‐oophorectomy: a retrospective analysis. BJOG 2011;118:28–33. Objectives To assess the significance of peritoneal washing cytology at the time of laparoscopic salpingo‐oophorectomy. Design Retrospective study. Setting Cambridge University Hospital. Population Four hundred and nine women who underwent laparoscopic salpingo‐oophorectomy by the gynaecology oncology team between 2004 and December 2009 were included. One hundred and thirteen women had risk‐reducing salpingo‐oophorectomy, 103 women had salpingo‐oophorectomy as part of breast cancer management, 59 had simple ovarian cysts, 111 had complex ovarian cysts and 23 had the procedure done for other reasons. Methods Histology and cytology results were reviewed and all hospital records were checked for subsequent malignancy. Sensitivity and specificity of peritoneal washing cytology was calculated. Main outcome measures Malignant peritoneal cytology in the absence of cancer on histopathology. Results Eleven of the 409 women in our study had occult malignancy on histopathological examination and three of them had positive peritoneal washings. One woman had positive washings from metastatic breast cancer. Thirteen women developed different malignancies subsequently but none had primary peritoneal or ovarian cancer within a median follow‐up interval of 34 months. Conclusions Peritoneal lavage cytology did not pick up any additional malignancy in the study population. Based on the evidence presented, we suggest that peritoneal washing cytology during laparoscopic salpingo‐oophorectomy is of limited value and should not be practised routinely.
- 4 November 2010
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 118 (1) , 28-33
Open AccessUtility of peritoneal lavage cytology during laparoscopic salpingo-oophorectomy: a retrospective analysis
Please cite this paper as: Haldar K, Giamougiannis P, Crawford R. Utility of peritoneal lavage cytology during laparoscopic salpingo‐oophorectomy: a retrospective analysis. BJOG 2011;118:28–33. Objectives To assess the significance of peritoneal washing cytology at the time of laparoscopic salpingo‐oophorectomy. Design Retrospective study. Setting Cambridge University Hospital. Population Four hundred and nine women who underwent laparoscopic salpingo‐oophorectomy by the gynaecology oncology team between 2004 and December 2009 were included. One hundred and thirteen women had risk‐reducing salpingo‐oophorectomy, 103 women had salpingo‐oophorectomy as part of breast cancer management, 59 had simple ovarian cysts, 111 had complex ovarian cysts and 23 had the procedure done for other reasons. Methods Histology and cytology results were reviewed and all hospital records were checked for subsequent malignancy. Sensitivity and specificity of peritoneal washing cytology was calculated. Main outcome measures Malignant peritoneal cytology in the absence of cancer on histopathology. Results Eleven of the 409 women in our study had occult malignancy on histopathological examination and three of them had positive peritoneal washings. One woman had positive washings from metastatic breast cancer. Thirteen women developed different malignancies subsequently but none had primary peritoneal or ovarian cancer within a median follow‐up interval of 34 months. Conclusions Peritoneal lavage cytology did not pick up any additional malignancy in the study population. Based on the evidence presented, we suggest that peritoneal washing cytology during laparoscopic salpingo‐oophorectomy is of limited value and should not be practised routinely.
- Open Access
- 1 April 2007
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 33 (2) , 95-98
Chlamydia screening and treatment in patients undergoing evacuation of retained products of conception or vaginal termination of pregnancy: an audit of the Royal College of Obstetricians and Gynaecologists' Guidelines in practice
Objective: To assess compliance with the Royal College of Obstetricians and Gynaecologists Guidelines regarding screening for and treatment of Chlamydia trachomatis before vaginal termination of pregnancy (VTOP) and surgical evacuation of retained products of conception (ERPC). Methods: Case notes of women undergoing VTOP and ERPC in the authors' department were examined for evidence of the presence of C. trachomatis infection and identification of chlamydia risk factors, and for evidence of curative treatment for women with confirmed infection or prophylactic treatment for women at risk. Results: In the VTOP group (n = 30) screening and treatment was carried out satisfactorily, aided by an assessment proforma. In the ERPC group (n = 30) there were weaknesses in the identification and treatment of patients at risk. Conclusions: We conclude that the use of a proforma helps to achieve effective screening. Adequate risk assessment of women undergoing ERPC seems to be difficult to achieve and so universal administration of prophylactic antibiotics might be a safe and efficient option until the National Chlamydia Screening Programme is established in our area.
- 1 April 2007
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 33 (2) , 95-98
Open AccessChlamydia screening and treatment in patients undergoing evacuation of retained products of conception or vaginal termination of pregnancy: an audit of the Royal College of Obstetricians and Gynaecologists' Guidelines in practice
Objective: To assess compliance with the Royal College of Obstetricians and Gynaecologists Guidelines regarding screening for and treatment of Chlamydia trachomatis before vaginal termination of pregnancy (VTOP) and surgical evacuation of retained products of conception (ERPC). Methods: Case notes of women undergoing VTOP and ERPC in the authors' department were examined for evidence of the presence of C. trachomatis infection and identification of chlamydia risk factors, and for evidence of curative treatment for women with confirmed infection or prophylactic treatment for women at risk. Results: In the VTOP group (n = 30) screening and treatment was carried out satisfactorily, aided by an assessment proforma. In the ERPC group (n = 30) there were weaknesses in the identification and treatment of patients at risk. Conclusions: We conclude that the use of a proforma helps to achieve effective screening. Adequate risk assessment of women undergoing ERPC seems to be difficult to achieve and so universal administration of prophylactic antibiotics might be a safe and efficient option until the National Chlamydia Screening Programme is established in our area.
- 25 January 2005
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 15 (1) , 175-179
The use of Palma's procedure in the salvage therapy for a leiomyosarcoma of the right pelvic sidewall: an intraoperative multidisciplinary approach
- 25 January 2005
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 15 (1) , 175-179
The use of Palma's procedure in the salvage therapy for a leiomyosarcoma of the right pelvic sidewall: an intraoperative multidisciplinary approach